secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2026-05-14T11:36:49+00:00
Accession:  0001193125-26-222818
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology Q1 2026 net loss $23.3M; MICVO data on track for mid-2026
------------------------------------------------------------------------

- Net loss $23.3M ($0.37/share) vs $21.2M ($0.35/share) YoY; R&D expenses rose to $20.0M from $17.0M.
- Cash and equivalents $42.5M; expected runway into Q4 2026.
- MICVO Phase 1 monotherapy update in 2L+ R/M HNSCC (dose cap patients) on track for mid-2026.
- MICVO + pembrolizumab Phase 1/2 combination dose escalation data in 1L R/M HNSCC expected 2H 2026.
- Appointed Nelson Azoulay as Chief Business Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000119312526222818/0001193125-26-222818-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000119312526222818/pyxs-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-222818

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer